Skip to main content
SpringerLink
Log in

Mitoxantrone-induced DNA strand breaks in cell-cultures of malignant human astrocytoma and glioblastoma tumors

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

In this study mitoxantrone (Mtx) induced DNA strand breaks were measured with the alkaline elution technique in short term cell cultures derived from human gliomas. Glioblastomas or astrocytomasfrom 5 patients who underwent intracranial surgery were cultured and incubated 1 h with different concentrations of Mtx (0, 0.01, 0.1 and 1.0 μg/ml). The alkaline elution methodwas modified to measure DNA lesions in human gliomas. Mtx inducedDNA strand breaks in a dose dependent manner in all cell culturestested. There was a linear increase of DNA strand break frequencyinduced by Mtx between 0.01—1.0 μg/ml. Concerning these in vitro data, Mtx might be potentially useful for the treatment ofpatients with malignant brain tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Koeller J, Eble M: Mitoxantrone: A novel anthracycline derivative. Clin Pharm 7: 574–581, 1988

    PubMed  Google Scholar 

  2. Lenk H, Müller U, Tanneberger S: Mitoxantrone: mechanism of action, antitumor activity, pharmacokinetics, efficacy in the treatment of solid tumors and lymphomas, and toxicity. Anticancer Res 7: 1257–1264, 1987

    PubMed  Google Scholar 

  3. Faulds D, Balfour JA, Chrisp P, Langtry HD: Mitoxantrone: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 41: 400–499, 1991

    PubMed  Google Scholar 

  4. Ehninger G, Schuler U, Proksch B, Zeller K-B, Blanz J: Pharmacokinetics and metabolism of mitoxantrone. Clin Pharmacokinet 18: 365–380, 1990

    PubMed  Google Scholar 

  5. Alberts DS, Peng YM, Bowden GT, Dalton WS, Mackel C: Pharmacology of mitoxantrone: mode of action and pharmacokinetics. Invest N Drugs 3: 101–107, 1985

    Google Scholar 

  6. Bowden GT, Roberts R, Alberts DS, Peng Y-M, Garcia D: Comparative molecular pharmacology in leukemic L 1210 cells of the anthracene anticancer drugs mitoxantrone and bisantrene. Cancer Res 45: 4915–4920, 1985

    PubMed  Google Scholar 

  7. Cohen LF, Glaubiger DL, Kann HE, Kohn KW: Protein associated DNA single strand breaks and cytotoxicity of dihydroxyanthracenedione (DHAD), NSC-301739, in mouse leukemia cells. Proc Am Ass Cancer Res 21: 277, 1980

    Google Scholar 

  8. Fox ME, Smith PJ: Long-term inhibition of DNA synthesis and persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone. Cancer Res 50: 5813–5818, 1990

    PubMed  Google Scholar 

  9. Basra J, Wolf CR, Brown JR, Patterson LH: Evidence for human liver mediated free-radical formation by doxorubicin and mitoxantrone. Anticancer Drug Design 1: 45–52, 1985

    Google Scholar 

  10. Fisher GR, Patterson LH: DNA strand breakage by peroxidase-activated mitoxantrone. J Pharm Pharmacol 43: 65–68, 1991

    PubMed  Google Scholar 

  11. Kohn KW, Ewig RAG, Erickson LC, Zwelling LA: Measurement of strand breaks and cross-links by alkaline elution. In: Friedberg EC, Hanawalt PC (eds) DNA Repair, a Laboratory Manual of Research Procedures, 379–401, 1981

  12. Kohn KW, Grimek-Ewig RA: Alkaline elution analysis, a new approach to the study of DNA single-strand interruptions in cells. Cancer Res 33: 1849–1853, 1973

    PubMed  Google Scholar 

  13. Nikkhah G, Tonn JC, Hoffmann O, Kraemer HP, Darling JL, Schönmayr R, Schachenmayr W: The MTT assay for chemosensitivity testing of human tumors of the central nervous system. Part I: Evaluation of test variables specific variables. J Neurooncol 13: 297–303, 1992

    Google Scholar 

  14. Cesarone CF, Bolognesi C, Santi L: Improved microfluorometric DNA determination in biological material using 33258 hoechst. Analytical Biochemistry 100: 188–197, 1979

    PubMed  Google Scholar 

  15. Heinemann V, Murray D, Walters R, Meyn RE, Plunkett W: Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine. Cancer Chemother Pharmacol 22: 205–210, 1988

    PubMed  Google Scholar 

  16. Jensen PB, Vindelov L, Roed H, Demant EJF, Sehested M: In vitroevaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL). Br J Cancer 60: 838–844, 1989

    PubMed  Google Scholar 

  17. Jones SE, Dean JC, Young LA, Salmon SE: The human tumor cologenic assay in human breast cancer. J Clin Oncol 3: 277–283, 1979

    Google Scholar 

  18. Salmon SE, Meyskens FL Jr, Alberts DS, Soehnlen B, Young L: New drugs in ovarian cancer and malignant melanoma: In vitrophase II screening with the human tumor stem cell assay. Cancer Treat Rep 65: 1–2, 1981

    Google Scholar 

  19. Dietel M, Arps H, Gerding D, Trapp M, Sieck M: Effectiveness of mitoxantrone on the proliferation of cell cultures derived from malignant mesenchymal tumors of human origin. J Cancer Res Clin Oncol 114: 197–203, 1988

    PubMed  Google Scholar 

  20. Kohn KW, Erickson LC, Ewig RAG, Friedman CA: Fractionation of DNA from mammalian cells by alkaline elution. Biochemistry 15: 4629–4635, 1976

    PubMed  Google Scholar 

  21. Nikkhah G, Tonn JC, Hoffmann O, Kraemer HP, Darling JL, Schachenmayr W, Schönmayr R: The MTT assay for chemosensitivity testing of human tumors of the central nervous system. Part II: Evaluation of patient-and drug-specific variables. J Neurooncol 13: 13–24, 1992

    PubMed  Google Scholar 

  22. Green RM, Stewart DJ, Hugenholtz H, Richard MT, Thibault M, Montpetit V: Human central nervous system and plasma pharamcology of mitoxantrone. J Neuro Oncol 6: 75–83, 1988

    Google Scholar 

  23. Stewart DJ, Hugenholtz H, Russel N, Richard MT, Banoit B, Maroun JA, Grahavac C, Girard A, Nabwangen JF: Phase II study of Novantrone (mitoxantrone hydrochloride) in adults with grade III–IV astrocytomas. In: Walker MD, Thomas DGT (eds) Biology of Brain Tumour, Martinus Nijhoff, Boston 411–413, 1986

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurosurgical Department, University of Giessen, W-6300 Giessen, Germany

    M. Senkal, U. Eickhoff, M. Kemen & E. Kollig

  2. Department of Neurosurgery, University of Würzburg, Germany

    J.C. Tonn

  3. Department of Neurosurgery, Dr. Horst-Schimdt Kliniken, Wiesbaden

    R. Scho¢nmayr

  4. Institute of Neuropathology, University of Giessen, Germany

    W. Schachenmayr

Authors
  1. M. Senkal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J.C. Tonn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Scho¢nmayr
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W. Schachenmayr
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. U. Eickhoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Kemen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E. Kollig
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Senkal, M., Tonn, J., Scho¢nmayr, R. et al. Mitoxantrone-induced DNA strand breaks in cell-cultures of malignant human astrocytoma and glioblastoma tumors. J Neurooncol 32, 203–208 (1997). https://doi.org/10.1023/A:1005792410604

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005792410604

Search

Navigation